Zambon discovered new CMS I-neb® therapy for the treatment of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB).
Colistimethate sodium powder for nebulization solution (CMS I-neb®) is a unique investigational treatment developed as potential first-in-class inhaled therapy for adult patients with NCFB. It delivers targeted concentrations of drug directly to the disease thus minimising systemic exposure which can cause toxicity and side effects.
CMS I-neb® lowers the disease rates of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB).
NCFB is a chronic disease which is irreversible. Currently, there are no inhaled treatments approved for patients with bronchiectasis and chronic P. aeruginosa colonization.
In Phase 3 PROMIS - I study, the effect of CMS I-neb® has significantly reduced the rates of NCFB and P. aeruginosa chronic infections in patients. Moreover, the trial has shown significant results when compared to placebo in reducing severe exacerbations and in improving quality life’s of people.
